Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8111966 | 0.89 | PTGS2 (0.70) | PTGS2PTGS1 | |
| SCHEMBL8423958 | 0.86 | PTGS2 (0.60) | PTGS2PTGS1 | |
| SCHEMBL6350819 | 0.85 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL6339181 | 0.83 | PTGS2 (0.84) | PTGS2PTGS1 | |
| SCHEMBL6452010 | 0.83 | PTGS2 (0.74) | PTGS2PTGS1 | |
| SCHEMBL6341762 | 0.82 | PTGS2 (0.82) | PTGS2PTGS1 | |
| SCHEMBL6341438 | 0.82 | PTGS2 (0.68) | PTGS2PTGS1 | |
| SCHEMBL6342540 | 0.82 | PTGS2 (0.82) | PTGS2PTGS1 | |
| SCHEMBL6349534 | 0.82 | PTGS2 (0.82) | PTGS2PTGS1 | |
| SCHEMBL6350704 | 0.82 | PTGS2 (0.72) | PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 315 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1332661-C | Methods of treating and preventing neoplasia using cyclooxygenase-2 inhibitors | SEARLE & CO (US) | 2007-08-22 | — | — | CN | claimed |
| CN-1767835-A | Compositions comprising cyclooxygenase-2 selective inhibitors and glucosamine for the treatment and prevention of pain and inflammation | PHARMACIA CORP (US) | 2006-05-03 | — | — | CN | claimed |
| EP-0843549-B1 | COMPOSITIONS COMPRISING A CYCLOOXYGENASE-2 INHIBITOR AND A LEUKOTRIENE A 4 HYDROLASE INHIBITOR | SEARLE & CO (US) | 2006-04-12 | — | — | EP | claimed |
| CN-1697654-A | Use of COx-2 inhibitors in combination with antiviral agents for the treatment of papilloma virus infections | UPJOHN CO (US) | 2005-11-16 | — | — | CN | claimed |
| CN-1660083-A | Method of using benzenesulphoamides that are cyclooxygenase-2-inhibitors in the treatment and prevention of neoplasia | G D SIORL & CO (US) | 2005-08-31 | — | — | CN | claimed |
| EP-0833622-B1 | COMPOSITIONS COMPRISING A CYCLOOXYGENASE-2 INHIBITOR AND A 5-LIPOXYGENASE INHIBITOR | SEARLE & CO (US) | 2005-08-10 | — | — | EP | claimed |
| EP-1539142-A2 | USE OF AN AMYLOID BETA VACCINATION IN COMBINATION WITH A SELECTIVE COX-2 INHIBITOR FOR THE TREATMENT OF ALZHEIMER S DISEASE | Pharmacia Corporation (US) | 2005-06-15 | — | — | EP | claimed |
| EP-1536863-A1 | USE OF CYCLOOXYGENASE-2 SELECTIVE INHIBITORS AND THROMBOLYTIC AGENTS FOR THE TREATMENT OR PREVENTION OF A VASO-OCCLUSIVE EVENT | Pharmacia Corporation (US) | 2005-06-08 | — | — | EP | claimed |
| US-20050026902-A1 | Methods and compositions for the treatment or prevention of human immunodeficiency virus and related conditions using cyclooxygenase-2 selective inhibitors and antiviral agents | PHARMACIA CORPORATION | 2005-02-03 | — | — | US | claimed |
| CN-1575182-A | Compositions for the treatment and prevention of pain and inflammation with a cyclooxygenase-2 selective inhibitor and chondroitin sulfate | PHARMACIA CORP (US) | 2005-02-02 | — | — | CN | claimed |
| US-20020035156-A1 | Combination therapy in the prevention of cardiovascular disorders | RONIKER BARBARA (US) | 2002-03-21 | — | — | US | claimed |
| US-20010047024-A1 | Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia | G.D. SEARLE & CO. | 2001-11-29 | — | — | US | claimed |
| EP-1079863-A1 | USE OF A COX-2 INHIBITOR AND A NK-1 RECEPTOR ANTAGONIST FOR TREATING INFLAMMATION | MERCK SHARP & DOHME LTD. (GB) | 2001-03-07 | — | — | EP | claimed |
| EP-0731796-B1 | 1,3,5-TRISUBSTITUTED PYRAZOLE COMPOUNDS FOR TREATMENT OF INFLAMMATION | SEARLE & CO (US) | 2000-08-02 | — | — | EP | claimed |
| CN-1253502-A | Method for preventing cardiovascular diseases using cyclooxygenase-2 inhibitor | SEARLE & CO (US) | 2000-05-17 | — | — | CN | claimed |
| CN-1247470-A | Methods of using cyclooxygenase-2 inhibitors as anti-angiogenic agents | SEARLE & CO (US) | 2000-03-15 | — | — | CN | claimed |
| CN-1244122-A | Methods of treating and preventing neoplasia using cyclooxygenase-2 inhibitors | SEARLE & CO (US) | 2000-02-09 | — | — | CN | claimed |
| WO-1999059635-A1 | USE OF A COX-2 INHIBITOR AND A NK-1 RECEPTOR ANTAGONIST FOR TREATING INFLAMMATION | MERCK SHARP & DOHME LIMITED (GB) | 1999-11-25 | — | — | WO | claimed |
| EP-0731796-A1 | 1,3,5-TRISUBSTITUTED PYRAZOLE COMPOUNDS FOR TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1996-09-18 | — | — | EP | claimed |
| WO-1995015318-A1 | 1,3,5-TRISUBSTITUTED PYRAZOLE COMPOUNDS FOR TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1995-06-08 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010047024-A1 | Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia | PTGS2, PTGES2, PTGS1 | PTGS2 1/4885PTGS1 3/4885 |
| US-20020035156-A1 | Combination therapy in the prevention of cardiovascular disorders | FABP3, TNNT2, TNNI3 | PTGS2 6/4885PTGS1 20/4885 |
| US-20050026902-A1 | Methods and compositions for the treatment or prevention of human immunodeficiency virus and related conditions using cyclooxygenase-2 selective inhibitors and antiviral agents | PTGS2, PTGS1, PTGES2 | PTGS2 1/4885PTGS1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.